Literature DB >> 16854841

A denileukin diftitox (Ontak) associated retinopathy?

J B Ruddle, C A Harper, D Hönemann, J F Seymour, H M Prince.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16854841      PMCID： PMC1857180          DOI： 10.1136/bjo.2006.091165

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  8 in total

1.  Confirmation of the activity of the interleukin-2 fusion toxin denileukin diftitox against chemorefractory chronic lymphocytic leukemia, including cases with chromosome 17p deletions and without detectable CD25 expression.

Authors:  Susan J Morgan; John F Seymour; H Miles Prince; David A Westerman; Max M Wolf
Journal:  Clin Cancer Res       Date:  2004-05-15       Impact factor: 12.531

2.  Lymphoma-associated retinopathy.

Authors:  King W To; Charles E Thirkill; Frederick A Jakobiec; Simmons Lessell; Eliot L Berson
Journal:  Ophthalmology       Date:  2002-11       Impact factor: 12.079

3.  Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  E Olsen; M Duvic; A Frankel; Y Kim; A Martin; E Vonderheid; B Jegasothy; G Wood; M Gordon; P Heald; A Oseroff; L Pinter-Brown; G Bowen; T Kuzel; D Fivenson; F Foss; M Glode; A Molina; E Knobler; S Stewart; K Cooper; S Stevens; F Craig; J Reuben; P Bacha; J Nichols
Journal:  J Clin Oncol       Date:  2001-01-15       Impact factor: 44.544

Review 4.  Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2.

Authors:  Angela M Thornton
Journal:  Front Biosci       Date:  2006-01-01

5.  Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies.

Authors:  Richard G Weleber; Robert C Watzke; William T Shults; Karmen M Trzupek; John R Heckenlively; Robert A Egan; Grazyna Adamus
Journal:  Am J Ophthalmol       Date:  2005-05       Impact factor: 5.258

6.  Waldenström's macroglobulinemia-associated retinopathy.

Authors:  H Nida Sen; Chi-Chao Chan; Rafael C Caruso; Robert N Fariss; Robert B Nussenblatt; Ronald R Buggage
Journal:  Ophthalmology       Date:  2004-03       Impact factor: 12.079

7.  Immune responses to retinal self-antigens in CD25(+)CD4(+) regulatory T-cell-depleted mice.

Authors:  Masaru Takeuchi; Hiroshi Keino; Takeshi Kezuka; Masahiko Usui; Osamu Taguchi
Journal:  Invest Ophthalmol Vis Sci       Date:  2004-06       Impact factor: 4.799

8.  Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy.

Authors:  Grazyna Adamus; Gaoying Ren; Richard G Weleber
Journal:  BMC Ophthalmol       Date:  2004-06-04       Impact factor: 2.209
  8 in total
  8 in total

Review 1.  Novel therapies in peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Hematol Malig Rep       Date:  2008-10       Impact factor: 3.952

Review 2.  Novel therapies in peripheral T-cell lymphomas.

Authors:  Hilary M O'Leary; Kerry J Savage
Journal:  Curr Oncol Rep       Date:  2008-09       Impact factor: 5.075

Review 3.  Current and emerging treatment strategies for cutaneous T-cell lymphoma.

Authors:  Frederick Lansigan; Francine M Foss
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

4.  Role of denileukin diftitox in the treatment of persistent or recurrent cutaneous T-cell lymphoma.

Authors:  Frederick Lansigan; Diane M Stearns; Francine Foss
Journal:  Cancer Manag Res       Date:  2010-02-05       Impact factor: 3.989

Review 5.  New roads open up for implementing immunotherapy in mesothelioma.

Authors:  R Cornelissen; M E Heuvers; A P Maat; R W Hendriks; H C Hoogsteden; J G J V Aerts; J P J J Hegmans
Journal:  Clin Dev Immunol       Date:  2012-06-24

Review 6.  Searching for the Achilles Heel of FOXP3.

Authors:  Teresa Lozano; Noelia Casares; Juan José Lasarte
Journal:  Front Oncol       Date:  2013-12-03       Impact factor: 6.244

7.  Blockage of FOXP3 transcription factor dimerization and FOXP3/AML1 interaction inhibits T regulatory cell activity: sequence optimization of a peptide inhibitor.

Authors:  Teresa Lozano; Marta Gorraiz; Aritz Lasarte-Cía; Marta Ruiz; Obdulia Rabal; Julen Oyarzabal; Sandra Hervás-Stubbs; Diana Llopiz; Pablo Sarobe; Jesús Prieto; Noelia Casares; Juan José Lasarte
Journal:  Oncotarget       Date:  2017-05-13

8.  Denileukin diftitox for the treatment of cutaneous T-cell lymphoma.

Authors:  David Kaminetzky; Kenneth B Hymes
Journal:  Biologics       Date:  2008-12
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.